Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00848250 · ClinicalTrials.gov registry record · NA
Angiotensin Converting Enzyme Inhibitors During Cardiopulmonary Bypass in Infants and Children
A NA study of Congenital Heart Disease, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT00848250: Completed NA study of Congenital Heart Disease, sponsored by Vanderbilt University Medical Center.
NCT00848250 is a NA study of Congenital Heart Disease that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 21 participants, below the 474-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00848250, a NA study of Congenital Heart Disease, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether ACE inhibitors alter the fibrinolytic, inflammatory, and hemodynamic response to cardiopulmonary bypass in infants and children with congenital heart disease.
Conditions Studied
Interventions
- DRUG Angiotensin Converting Enzyme Inhibitor
- OTHER No ACE Inhibitor
Study Locations (1)
Tennessee
- Monroe Carell Jr. Children's Hospital at Vanderbilt - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2008-09 |
| Est. Completion | 2010-07 |
| Phase | NA |
What the finished NCT00848250 record still lists
NCT00848250 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 474-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Congenital Heart Disease appearing as the primary indexed condition, and to 2 interventions - of which Angiotensin Converting Enzyme Inhibitor is the first listed.
NCT00848250 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT00848250 about?
NCT00848250 is a clinical study titled "Angiotensin Converting Enzyme Inhibitors During Cardiopulmonary Bypass in Infants and Children". The purpose of this study is to determine whether ACE inhibitors alter the fibrinolytic, inflammatory, and hemodynamic response to cardiopulmonary bypass in infants and children with congenital heart disease.
What is the current status of trial NCT00848250?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2008-09. Estimated completion is 2010-07.
What conditions does trial NCT00848250 study?
This clinical trial studies the following conditions: Congenital Heart Disease.
What interventions are being tested in trial NCT00848250?
The interventions under investigation include: Angiotensin Converting Enzyme Inhibitor (DRUG), No ACE Inhibitor (OTHER).
Who is sponsoring clinical trial NCT00848250?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00848250 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congenital Heart Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00848250's enrollment target sits among peer trials
21 61st of 63 higher than 3 of 63 other Congenital Heart Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Congenital Heart Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fontan Fitness Trial
RECRUITING · NA
-
Blood Conservation in Patients (3.5-12kg) Undergoing Congenital Cardiac Surgery
RECRUITING · NA
-
The Sequencing for Detection in Congenital Heart Disease (SD-CHD) Study
RECRUITING · NA
-
Starlight Cardiovascular Lifeline Ductus Arteriosus Stent IDE Study
RECRUITING · NA
-
A Study of Hemodynamic Cardiopulmonary Exercise for CHD
RECRUITING · NA
-
Ventripoint Single Ventricle Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia